Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment

BACKGROUND: Recently, new direct-acting antivirals (DAAs) are known to eradicate chronic hepatitis C (CHC) virus infection and prevent the progression of liver fibrosis. Liver fibrosis may predispose to liver cirrhosis or hepatocellular carcinoma. We investigated the effect of DAAs on liver fibrosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sun Hee, Shin, Hyun Phil, Lee, Joung Il
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683836/
https://www.ncbi.nlm.nih.gov/pubmed/33215505
http://dx.doi.org/10.1177/2040206620974835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683836/
https://www.ncbi.nlm.nih.gov/pubmed/33215505
http://dx.doi.org/10.1177/2040206620974835

Ejemplares similares